在远端半径骨折手术后治疗骨质疏松症的zoledronic酸:前性的纵向研究
Shu Yoshizawa1, Takanori Shintaku2, Hideaki Ishii2
1Department of Orthopedic Surgery(Ohashi), Toho University Graduate School of Medicine, Tokyo, Japan.
Journal of orthopaedics
|August 10, 2023
概括
在远距离半径骨折 (DRF) 后,早期使用索莱德龙酸治疗骨质疏松症的干预改善了骨矿物质密度,并减少了二次骨折. 积极的治疗对于预防DRF患者进一步的脆弱性骨折至关重要.
科学领域:
- 整形外科 整形外科 整形外科
- 内分泌学 在内分泌学.
- 老年病的医生 老年病的医生
背景情况:
- 远半径骨折 (DRF) 是最常见的最初的骨质疏松性脆弱性骨折.
- 目前的治疗往往侧重于骨折本身,忽视了潜在的骨质疏松症.
- 对骨质疏松症的早期干预对于防止随后的骨折至关重要.
研究的目的:
- 为了研究早期骨质疏松症干预的有效性,在患有DRFs的患者中使用zoledronic acid.
- 评估龙酸对骨矿物质密度 (BMD) 和骨周转标记物的影响.
- 为了评估二次骨折和骨融合后治疗的发生率.
主要方法:
- 一项针对30名手术治疗DRF患者 (≥50岁) 的前性研究.
- 佐勒多尼酸 (5毫克静脉注射) 给腰椎或大腿骨骨质量<年轻成年人平均值 (YAM) 的80%的患者.
- 监测和分析了BMD,TRACP-5b和PINP水平;评估了不良影响.
主要成果:
- 平均基线BMD为76.1% (脊柱) 和70.7% (股骨) YAM,表明骨质疏松症.
- 在治疗后观察到显著的BMD改善,5名患者在60个月内达到>80%的YAM.
- 骨循环标记 (TRACP-5b,PINP) 也显示出显著的变化;40%的患者出现了与年龄,BMI或肌素清除无关的不良药物反应.
- 骨融合发生在平均3.6个月后;3名患者在60个月内遭受了二次骨折.
结论:
- 与其他脆弱性骨折相比,DRF发生在较年轻的年龄.
- 强化骨质疏松治疗,包括乙酸,在DRF后至关重要,以防止二次骨折.
- 早期干预可以改善骨健康并降低随后骨质疏松事件的风险.
相关概念视频
01:27Fractures: Bone Repair
3.3K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
3.3K
01:31Osteoclasts in Bone Remodeling
3.0K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.0K